DeCure for Gastrointestinal defects and immunodeficiency syndrome 1
DeCure's autonomous Immuno AI scientist is researching a drug-repurposing hypothesis for gastrointestinal defects and immunodeficiency syndrome 1 — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleGastrointestinal defects and immunodeficiency syndrome 1 maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for gastrointestinal defects and immunodeficiency syndrome 1 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
adenosine deaminase (ADA) — ADA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2r,3s,5rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3IAR · 1.52 Å · ligand (2R,3S,5R)-5-(6-amino-9H-purin-9-yl)-tetrahydro-2-(hydroxymethyl)furan-3-ol (3D1). Experimental structure, not a prediction.
What the evidence adds up to
A 1997 review notes that gastrointestinal infections are common in patients with acquired immunodeficiency syndrome because the gut is a major site for opportunistic infections and neoplasms, and that therapies for a number of these disorders are both widely available and highly effective. A 2001 chapter states that gastrointestinal disease secondary to non-HIV immunosuppression remains relatively uncommon outside transplantation medicine, and that inflammation in primary immunodeficiency disorders is typically refractory even to intense immunosuppression, with bone marrow transplantation being the treatment of choice. A 2022 chapter adds that HIV infection should be considered routinely in patients presenting with features of immunodeficiency, and that intractable diarrhoea, malabsorption, opportunistic gastrointestinal infections, and failure to thrive in children should prompt consideration of associated primary immunodeficiency.
A 2016 case report describes an elderly woman with HIV-1 infection who developed short bowel syndrome after extensive intestinal resection. A single-dose test of six antiretroviral drugs (darunavir, ritonavir, lopinavir, etravirine, maraviroc, and raltegravir) did not provide information on the appropriate drug. Repeated therapeutic drug monitoring under continuous antiretroviral therapy resulted in viral suppression below 50 copies/mL, considered treatment success. The authors suggest the importance of therapeutic drug monitoring in the steady state for successful treatment of individuals with impaired gastrointestinal function using antiretrovirals.
No abstract in this set reports a controlled trial of any drug specifically for gastrointestinal defects and immunodeficiency syndrome 1. The 1997 and 2001 reviews are general and do not name a specific drug regimen with survival or response rates for this condition. The 2022 chapter does not provide concrete numbers. The 2016 case report involves a single patient with HIV and short bowel syndrome, not the primary immunodeficiency named in the query.
What is still missing is any prospective trial or systematic data on drug repurposing for gastrointestinal defects and immunodeficiency syndrome 1. No abstract provides a sample size, response rate, or survival statistic for this specific disease. The evidence consists of general reviews and a single case report on a different immunodeficiency. No trial design, patient stratification strategy, or funding for such a study is described.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
The therapy of gastrointestinal infections associated with the acquired immunodeficiency syndrome
AbstractAlthough there have been dramatic strides in the therapy of human immunodeficiency virus infection over the last few years, the number of infected people world-wide is tremendous and, at least in developing countries, continues to expand. Complications which involve the gastrointestinal tract are common in these patients, because the gut is a major site for involvement by opportunistic infections and neoplasms in patients with the acquired immunodeficiency syndrome. It is important to recognize the clinical spectrum of gastrointestinal diseases, as well as the appropriate and most cost-effective diagnostic strategies, as therapies for a number of these disorders are both widely available and high effective. This review summarizes the major gastrointestinal infections which are seen in patients with the acquired immunodeficiency syndrome, and their treatment.
Internal Medicine · 2016 · 13 citations · open access
Therapeutic Drug Monitoring of Anti-human Immunodeficiency Virus Drugs in a Patient with Short Bowel Syndrome
AbstractAn elderly woman with human immunodeficiency virus-1 infection developed short bowel syndrome as a result of extensive intestinal resection. Considering the possibility of poor absorption of antiretroviral drugs (ARVs), therapeutic drug monitoring (TDM) was performed. A single-dose test of 6 ARVs (darunavir, ritonavir, lopinavir, etravirine, maraviroc, and raltegravir) did not provide information on the appropriate ARV, and repeated TDM under continuous antiretroviral therapy resulted in viral suppression below 50 copies/mL, which was considered to be treatment success. These assessments suggest the importance of TDM in the steady state for the successful treatment of individuals with impaired gastrointestinal function using ARVs.
Gastrointestinal Problems in the Immunocompromised
AbstractGastrointestinal disease secondary to immunosuppression that is not associated with human immunodeficiency virus (HIV) remains relatively uncommon outside transplantation medicine, therefore the majority of this chapter will review the clinical presentation, diagnosis, and treatment of HIV-associated gastrointestinal disease. Gastrointestinal disease caused by iatrogenic and familial immunosuppression will be discussed briefly at the end of the chapter.
Yamada's Textbook of Gastroenterology · 2022 · 0 citations
Immunological disorders: (b) immunodeficiencies and gastrointestinal complications of organ transplantation
AbstractA specific and important secondary immunodeficiency disorder is acquired immunodeficiency syndrome. HIV infection should be considered routinely in all patients presenting with features of immunodeficiency and approach to screening should be liberal, noting that in some immunodeficiencies where antibody production is compromised, antibody-based screening is not valid and antigenic testing is required. Intractable diarrhea, malabsorption, opportunistic or unusual gastrointestinal infections, atypical histological features in presumed inflammatory bowel diseases, and, in children, failure to thrive should all prompt consideration of associated primary immunodeficiency. Primary immunodeficiency disorders with prominent or important gastrointestinal manifestations are discussed in this chapter. Inflammation is typically refractory even to intense immunosuppression and bone marrow transplantation is the treatment of choice. Gastrointestinal complications are common in patients undergoing organ and tissue transplantation.
Oxford University Press eBooks · 2013 · 0 citations
Introduction to Disorders Associated with DNA Repair and Methylation Defects
AbstractPrimary immunodeficiency diseases are inherited disorders that affect human adaptive and innate immunity. In most cases, affected individuals experience recurrent infections, but they may also suffer from autoimmune diseases and malignancies. This chapter focuses on disorders associated with DNA repair and methylation defects,including the historic and scientific background, clinical presentations, immunologic characteristics, and the molecular/genetic underpinnings. Where appropriate, diagnostic tools and therapeutic options are outlined -- from prophylactic anti-infective measures to hematopoietic stem cell transplantation and gene therapy.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
